• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes

Professional Introduction to Compound with CAS No 654662-97-2 and Product Name: 4-2-(2-methylphenyl)ethylpiperidine

The compound with the CAS number 654662-97-2 and the product name 4-2-(2-methylphenyl)ethylpiperidine represents a significant advancement in the field of pharmaceutical chemistry. This compound belongs to a class of molecules known for their potential in modulating neurological pathways, making it a subject of considerable interest in both academic research and industrial applications. The structural features of this molecule, particularly its piperidine core and the 2-methylphenyl substituent, contribute to its unique pharmacological profile, which has been the focus of recent studies.

In recent years, there has been a growing interest in developing novel therapeutic agents that target central nervous system (CNS) disorders. The piperidine scaffold is well-known for its role in various pharmacologically active compounds due to its ability to interact with multiple neurotransmitter systems. The introduction of the 4-2-(2-methylphenyl)ethyl side chain into this framework enhances the compound's potential by altering its solubility, bioavailability, and binding affinity to specific receptors. These modifications are critical in designing molecules that exhibit improved efficacy and reduced side effects compared to their predecessors.

One of the most compelling aspects of 4-2-(2-methylphenyl)ethylpiperidine is its potential as a precursor for further derivatization. Researchers have been exploring various synthetic pathways to modify this core structure, aiming to identify derivatives with enhanced pharmacological properties. For instance, studies have shown that introducing additional functional groups at specific positions on the piperidine ring can significantly alter the compound's receptor binding affinity. This flexibility makes 4-2-(2-methylphenyl)ethylpiperidine a valuable scaffold for medicinal chemists seeking to develop new treatments for conditions such as depression, anxiety, and neurodegenerative diseases.

The 2-methylphenyl moiety in 4-2-(2-methylphenyl)ethylpiperidine is particularly noteworthy due to its ability to influence the compound's metabolic stability and interaction with metabolic enzymes. Recent research has highlighted the importance of optimizing this substituent to achieve the desired pharmacokinetic profile. By fine-tuning the size and electronic properties of the methylphenyl group, scientists can modulate how quickly the compound is metabolized and eliminated from the body. This is crucial for ensuring that therapeutic effects are sustained over time while minimizing potential adverse reactions.

Advances in computational chemistry have also played a pivotal role in understanding the behavior of 4-2-(2-methylphenyl)ethylpiperidine. Molecular modeling techniques allow researchers to predict how this compound will interact with biological targets at an atomic level. These simulations have been instrumental in guiding synthetic efforts and identifying promising derivatives. For example, virtual screening has been used to identify structural analogs of 4-2-(2-methylphenyl)ethylpiperidine that may exhibit improved binding affinity or selectivity for specific receptors involved in CNS disorders.

The synthesis of 4-2-(2-methylphenyl)ethylpiperidine involves multiple steps, each requiring careful optimization to ensure high yield and purity. Recent innovations in synthetic methodologies have enabled more efficient production processes, reducing costs and environmental impact. Techniques such as flow chemistry and catalytic hydrogenation have been particularly useful in streamlining the synthesis of complex molecules like this one. These advancements not only improve the accessibility of 4-2-(2-methylphenyl)ethylpiperidine but also set the stage for large-scale production if it proves successful in clinical trials.

Evaluation of 4-2-(2-methylphenyl)ethylpiperidine in preclinical models has provided valuable insights into its potential therapeutic applications. Studies have demonstrated its ability to modulate neurotransmitter release and receptor activity, suggesting its utility in treating a range of CNS disorders. However, further research is needed to fully understand its mechanism of action and long-term safety profile. Preclinical trials are ongoing to assess its efficacy and tolerability in animal models, paving the way for potential human trials.

The future prospects for 4-2-(2-methylphenyl)ethylpiperidine are promising, given its unique structural features and potential as a pharmacological tool. As our understanding of CNS disorders continues to evolve, so too will our approaches to developing effective treatments. The compound's versatility as a scaffold for further derivatization ensures that it will remain a topic of interest for years to come. Researchers are optimistic that optimized derivatives will eventually lead to novel therapeutics that address unmet medical needs.

In conclusion,4-2-(2-methylphenyl)ethylpiperidine, with its CAS number 654662-97-2, represents a significant contribution to pharmaceutical chemistry. Its structural design offers exciting possibilities for modulating neurological pathways, making it a valuable candidate for further research and development. As scientific understanding progresses, this compound is poised to play an important role in shaping future treatments for CNS disorders.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)